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Korean Women with Stage I Breast Carcinoma: An Initial Report of the Korean
Radiation Therapy Oncology Group (KROG) Study 0804
Purpose
This prospective study was designed to verify the technical feasibility of partial breast
irradiation in breast cancer patients with small breasts, which are commonly encountered
in Korean women.
Materials and Methods
A total of 40 Gy, administered in 10 fractions on consecutive days (one fraction per day),
was prescribed to the isocenters of the fields using three-dimensional conformal radiother-
apy (3-DCRT). For all patients, treatment planning and dose parameters strictly adhered to
the constraints set forth in the Radiation Therapy Oncology Group (RTOG) 0319 protocol.
This study was designed such that if fewer than five of the first 42 evaluable patients re-
ceived unacceptable scores, the treatment would be considered reproducible.
Results
Ten treatment plans (23.8%) were determined to have major variations. There was no major
variation in planning target volume (PTV) coverage. The ipsilateral and contralateral breast
dose limitations were not met in four (9.5%) and four cases (9.5%), respectively. Major
variations in ipsilateral and contralateral lung dose limitations were observed in two cases
(4.8%). Major variations in the heart and thyroid dose limitations were observed in one
(2.4%) and one case (2.4%), respectively. In multivariate analysis, a ratio of PTV to ipsilateral
breast volume (PTV/IB) > 0.16 was the only significant factor that statistically affected major
variations. 
Conclusion
We concluded that partial breast irradiation using 3-DCRT could not be reproduced in
Korean breast cancer patients, particularly small-volumed breast surrogated as PTV/IB
> 0.16. The dominant cause was the major variation in surrounding normal breast tissues.
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Introduction
A systematic review and meta-analysis of the current
randomized trials to evaluate the role of accelerated partial
breast irradiation (APBI) in eligible breast cancer patients
suggested that APBI did not appear detrimental to survival
and could be used as an alternative to whole breast irradia-
tion (WBI) [1-3]. In selected patients, APBI, with fewer larger
fractions delivered over a shorter time, could be an alterna-
tive to WBI because most relapses occur near the lumpec-
tomy site [4-6].
The high “elsewhere” failure throughout the review of
APBI frontier studies indicated the importance of appropri-
ate patient selection and optimal APBI techniques [7]. A
phase II study of APBI using proton therapy conducted in
Korea showed excellent disease control [8]. However, only
one center in Korea is equipped with proton therapy.
Therefore, we adopted the three-dimensional conformal ex-
ternal beam radiotherapy (3-DCRT) technique for partial
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
Correspondence: Sung-Ja Ahn, MD, PhD
Department of Radiation Oncology,
Chonnam National University Hwasun
Hospital, Chonnam National University
Medical School, 322 Seoyang-ro,
Hwasun 519-763, Korea
Tel: 82-61-379-7200
Fax: 82-61-379-7249
E-mail: ahnsja@chonnam.ac.kr
Received  October 18, 2013
Accepted  December 17, 2013
Published online  August 21, 2014
Jae-Uk Jeong, MD1
Jung Han Yoon, MD, PhD2
Min Ho Park, MD, PhD2
Mee Sun Yoon, MD, PhD1
Ju-Young Song, PhD1
Taek-Keun Nam, MD, PhD1
Woong-Ki Chung, MD, PhD1
Yong-Hyub Kim, MD1
Chang-Ok Suh, MD, PhD3
Sung-Ja Ahn, MD, PhD1
Departments of 1Radiation Oncology and
2Surgery, Chonnam National University
Medical School, Gwangju,
3Department of Radiation Oncology,
Yonsei University College of Medicine,
Seoul, Korea
Original Article
Jae-Uk Jeong, Partial Breast Irradiation in Korean Women
VOLUME 47  NUMBER 1  JANUARY  2015  19
breast irradiation (PBI) because it is noninvasive, compared
with brachytherapy or intraoperative therapy, and readily
available in many institutions. The Radiation Therapy
Oncology Group (RTOG) 0319 study reported that the
technical feasibility of 3-DCRT for APBI was acceptable
[9,10]. However, the 3-DCRT approach treats comparatively
large normal breast tissue volumes while delivering
relatively homogeneous doses to the target volume, as the
basic underlying principle for the successful application of
PBI is balanced radiation delivery between the planning
target volume (PTV) and normal breast tissue.
We need to determine whether the technical feasibility
confirmed in Western breast cancer patients could be equally
applicable to Korean women, who have relatively small
breasts compared to Western women. Therefore, we
designed phase I and II clinical trials to evaluate the technical
feasibility of 3-DCRT in Korean breast cancer patients, using
the technique confirmed by RTOG 0319, to determine the
types of variations that occur during PBI with 3-DCRT in
small-volumed breast cancer patients. This is the first report
of the technical feasibility of PBI with 3-DCRT in Korea.
Materials and Methods
1. Patient eligibility
We defined the inclusion criteria more strictly than that of
RTOG 0319; the criteria were postmenopausal women, a
unifocal tumor, tumor size  2 cm with a resection margin
(RM) > 2 mm, negative sentinel or axillary nodes, hormone
receptor positivity, and a good to excellent postoperative
cosmesis score [11]. Patients with histological evidence of
lymphovascular invasion, an extensive intraductal compo-
nent, lobular histological type, ductal carcinoma in situ or
lobular carcinoma in situ, and wound issues were excluded.
Patients who received chemotherapy were also excluded.
Radiation must have been initiated within eight weeks after
surgery. The institutional review board approved this phase
I/II trial, and all patients were prospectively enrolled and
submitted consent forms.
2. Treatment techniques and imaging
Patients were immobilized in the supine position with both
arms elevated upward, using a vacuum immobilization
device. The ipsilateral whole breast and breast surgical scar
were marked with a radiopaque rubber catheter. A treatment
planning computed tomography (CT) scan (Hi-Speed FX/I,
GE Medical Systems, Milwaukee, WI) was performed at a 3-
mm scan width, and a contrast-enhanced image was ob-
tained. The scan began at or above the mandible to beyond
the breast tissue, including the entire lung. We used the
Varian Eclipse treatment planning system (Varian Medical
Systems, Palo Alto, CA). The following structures were con-
toured manually by the radiation oncologist: the lumpec-
tomy cavity (LC) volume, PTV, ipsilateral breast,
contralateral breast, thyroid, ipsilateral and contralateral
lungs, and heart. We defined the target volume from the LC.
To reduce the variability in LC contouring, radiation oncol-
ogists who participated in this study were educated and
accustomed to the target volume definition guidelines. We
assigned a clarity visualization score (CVS) to each patient,
as follows; CVS-1, no cavity visualized; CVS-2, cavity
visualized but significant uncertain margins; CVS-3, cavity
visualized with some uncertain margins; CVS-4, cavity with
mild heterogeneity on CT and mostly distinct margins;
CVS-5, homogenous cavity with clearly identified margins
[12]. The PTV was nonuniformly expanded 5-15 mm around
the LC, depending on the safety margin widths along the six
directions (superior, inferior, medial, lateral, superficial, and
deep) described in the surgical pathologic report. We set a
1.5 cm expansion if the RM was < 1 cm, a 1-cm expansion if
the RM was between  1 cm and < 2 cm, and a 0.5 cm expan-
sion if the RM was  2 cm in all six directions. The PTV
excluded the skin, was confined to a maximum of 5 mm
under the skin, and vexcluded the underlying lung by
lung-chest wall interface. Ipsilateral and contralateral breast
included all tissue volume, excluding pectoralis muscles,
chest wall muscles, and ribs as recommended by RTOG.
The treatment was administered with three-dimensional
conformal fields, and intensity-modulated radiation therapy
was not allowed. Three or four non-coplanar beams that
used 6-MV photons or a mixed-modality plan that used a
photon field with an en face electron field were used. The
maximum dose should not exceed 110% of the prescribed
dose. We followed the radiotheraphy delivery technique and
dosimetric guidelines for dose volume constraints set forth
by the RTOG 0319 study. A thorough review of the dose
volume histogram of each patient was performed by both the
radiation oncologist and physicist, and a quality assurance
evaluation of the treatment plans was performed to deter-
mine the variations.
Each plan was scored as acceptable (per protocol), margin-
ally acceptable (minor variation), or unacceptable (major
variation). An acceptable plan showed 95% isodose surface
covers 100% of the PTV, and all specified critical normal
tissue dose limits have been met. A marginally acceptable
plan showed 95% isodose surface covers between  95% to
< 100% of the PTV, and all specified critical normal tissue
dose limits fall within 5%. An unacceptable plan showed 95%
isodose surface covers < 95% of the PTV, or any critical
normal tissue dose limit exceeding 5% of the specified value.
Each dose limitation for normal tissues followed the criteria
described in the RTOG 0319 protocol [9].
In brief, less than 50% of the ipsilateral whole breast should
receive  50% of the prescribed dose and less than 25% of the
whole breast should receive the prescribed dose. The con-
tralateral breast should receive less than 3% of the prescribed
dose to any point. At most, less than 10% of the ipsilateral
lung can receive 30% of the prescribed dose and less than
10% of the contralateral lung should receive 5% of the pre-
scribed dose. In right-sided lesions, less than 5% of the heart
should receive 5% of the prescribed dose in a while the vol-
ume of the heart receiving 5% of the prescribed dose should
be less than that for treatment using conventional whole
breast radiation with tangential fields in left-sided lesions.
Maximum point dose in thyroid should be less than 3% of
the prescribed dose.
A total of 40 Gy, given in 10 fractions on consecutive days,
one fraction per day, were prescribed to the isocenters of the
fields. Electronic portal imaging was monitored for the first
session and repeated at the sixth radiotherapy session. No
patients received chemotherapy, and adjuvant endocrine
therapy was combined with radiotherapy in all patients.
3. Statistical considerations
Technical feasibility was the primary end point in this
study. A final review of the plan as acceptable or marginally
acceptable indicated that the technique is reproducible. An
optimal two-stage Simon design was used for this trial. Let
p-value be the true probability that the final review is accept-
able or marginally acceptable. A p-value close to 1 implies
that the radiation therapy is reproducible in a multi-center
setting. If p-value is  80%, the goal is to have at most a 5%
probability of concluding that the technique is reproducible.
On the other hand, if p-value is  95%, the desired level, the
goal is to have at most a 10% probability (five cases) of
concluding that the technique is not reproducible in the first
42 evaluable treatment plans. Associations with pretreatment
factors, including the tumor location, tumor side, ipsilateral
breast volume, PTV volume, and PTV volume to ipsilateral
breast volume ratio (PTV/IB) were tested using the
chi-square test and logistic regression. Fisher’s exact test was
used with small sample sizes (< 5 in any cells) in  univariate
analysis. All statistical data were processed using SPSS ver.
19.0 (SPSS Inc., Chicago, IL), and null hypotheses were
rejected at p < 0.05.
Values are presented as number (%). PBI, partial breast
irradiation; pT stage, pathologic T stage; PTV, planning
target volume; PTV/IB, planning target volume to ipsilat-
eral breast volume ratio.
Table 1. Patient characteristics
PBI (n=42)
Age (yr)
Median 62.0
Range 50-76
pT stage
mi 2 (4.8)
1a 2 (4.8)
1b 14 (33.3)
1c 24 (57.1)
Tumor size (cm)
Median 1.1
Range 0.1-1.9
Tumor side
Right 12 (28.6)
Left 30 (71.4)
Tumor location
Upper outer 26 (61.8)
Upper inner 3 (7.1)
Lower outer 4 (9.5)
Lower inner 2 (4.9)
Upper central 6 (14.3)
Lower central 1 (2.4)
Cavity visualization score
2 1 (2.4)
3 11 (26.2)
4 19 (45.2)
5 11 (26.2)
Lumpectomy cavity (mL)
Median 34.88 
Range 15.40-86.73 
PTV (mL)
Median 108.94 
Range 59.59-185.67 
Ipsilateral breast volume (mL)
Median 784.18 
Range 337.58-1,476.60 
PTV/IB
Median 0.1481
Range 0.07-0.23
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Results
1. Patient characteristics
A total of 42 patients were enrolled in this study between
January 2009 and July 2013. The pretreatment characteristics
are shown in Table 1. The median age of patients was 62
years, and the median tumor size was 11 mm. The tumor
location was the outer or central quadrant for 37 patients
(88%) and the inner quadrant for five patients (12%). The
median LC volume at the time of treatment planning was
34.88 mL. The median PTV volume was 108.94 mL. The
median ipsilateral whole breast volume was 784.18 mL. The
median PTV/IB ratio was 0.1481 (Table 1).
2. Technical feasibility
Results of the plan evaluation with regard to dosimetric
variations for the 42 patients, upon which the decision of
feasibility was based, are shown in Table 2. There were no
variations in 18 patients (42.9%) and minor variations in 14
patients (33.3%). Ten treatment plans (23.8%) were deter-
mined to have major variations, all of which were related to
normal tissue dose constraints that exceeded 5% of the
specified limit. There were no major variations in the PTV
coverage. Figs. 1 and 2 show dose distribution and dose
volume histogram of a case determined to have no major
variation.
We analyzed the relationship between the tumor or normal
tissue parameters and major variations in the treatment plans
(Table 3). Of 12 patients with PTV > 130 mL, six (50%) had
major variations. However, only four of 30 patients (13.3%)
with PTV  130 mL had major variations. Major variations
were observed more frequently in patients with PTV/IB
> 0.16 (seven of 15 patients, 46.7%) than in patients with
PTV/IB  0.16 (three of 27 patients, 11.1%). In multivariate
analysis, the PTV/IB showed statistical significance affecting
the major variation.
3. Dosimetric features in cases with major variations
Dose limitations in the ipsilateral and contralateral breast
were not met in four (9.5%) and four cases (9.5%), respec-
tively. Case no. 13 had major variations in both ipsilateral
and contralateral breast dose limitations (Table 4). In this
case, PTV was more than 130 mL (148.16 mL) and PTV/IB
was more than 0.16 (0.19). In the four cases with major
ipsilateral breast variations, all had PTV/IB > 0.16, and three
cases had PTV > 130 mL. Six cases with PTV > 130 mL (case
nos. 9, 13, 18, 27, 28, and 42) and seven with PTV/IB > 0.16
(case nos. 13, 18, 23, 27, 28, 31, and 42) had major
variations. Among these cases, four with PTV > 130 mL
(66.7%) and five with PTV/IB ratios > 0.16 (71.4%) did not
fit the ipsilateral or contralateral breast dose limitations.
In the analysis of ipsilateral lung dose constraints, two
cases (4.8%) showed major variations. Ipsilateral breast
volumes < 900 mL and PTV/IB ratios > 0.16 were observed
in both cases. In two cases with major variations in the
contralateral lung dose limitation, we did not observe any
specific features. Only one case (2.4%) had a major variation
in the heart. In this case, the tumor was located in the lower
central portion of the right breast. Although an electron beam
was used in part in this case, more than 2 Gy were delivered
to the right atrium. A thyroid dose limitation was observed
in one case (2.4%). In this case, the LC was in the upper
quadrant of the left breast, near the thyroid gland (Table 4).
Discussion
As clinical experiences with PBI increase, it is certain that
patient subsets might be adequately treated with PBI, with
acceptably low recurrence rates. As PBI currently remains an
investigational approach and is not yet a standard therapy,
we designed this study to include a more rigorously selected
group of patients than would be allowed by the “suitable”
criteria suggested in the American Society for Radiation
Fig. 1. Dose distribution of partial breast irradiation using
two coplanar and two non-coplanar photon beams.
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Oncology consensus statement [2]. We further limited
eligible patients for this study to those without wound issues
and chemotherapy and those with good to excellent cosmesis
scores at the time of radiotherapy.
Delineation of the optimal treatment volume required to
obtain equal or better local control rates, compared with
WBI, after conservative surgery is crucial to the precision of
conformal radiation therapy planning and the validity of
clinical trial results [13]. The issue of surgical clips during LC
visualization when performing PBI with 3-DCRT has been
highlighted as mandatory [14]. However, surgeons at our
institute do not use surgical clips; therefore, we used the LC
to define the PBI treatment target. In a study of change of the
serial morphologic cavity after surgery, the optimal time to
delineate the target volume from the excision cavity in the
planning CT scan for PBI was reported to be within eight
weeks [15]. Based on this data, we limited study entry to
patients who could undergo PBI within eight weeks after
surgery. Variability among radiation oncologists regarding
delineation of the postsurgical LC could be decreased with a
CVS  3 [12]. In our study, CVS < 3 was observed in only one
patient. For this patient, when defining the LC, we obtained
a consensus among radiation oncologists to include all
surgical tissue extensions. We chose a different method to
define the PTV than that used in the RTOG 0319 study. We
differentiated the optimal margin to be included in the PTV
according to the surgical safety margin. This was meant to
provide the same final margin to the gross tumor area in all
patients, irrespective of the extent of volume surrounding the
gross tumor that was surgically removed.
The widespread acceptance of APBI using the 3-DCRT
approach is likely because it is totally noninvasive and
delivers a homogenous dose distribution to the target
volume. In our study, PTV was defined to exclude the skin
(5 mm beneath the skin surface) in order to reduce skin
toxicity [16] and there was no case in which skin should be
included in PTV due to positive or close superficial RM. And,
there was no major variation in the PTV coverage because
the beam-aperture was composed to cover the PTV. The
majority of the major variation was caused by the inability
to fit the dose constraints on normal breast tissue. The
surrounding normal tissue dose-volume relationship is a
critical underlying factor, in accordance with the dosimetric
guidelines. Regarding the PTV/IB ratio, large target volumes
(PTV) contribute to an increased risk of severe fibrosis and
poor cosmesis [17]. Leonard et al. [18] reported a clear and
statistically significant association between the dose-volume
parameters and late moderate-to-severe breast toxicity. The
relative volumes of breast tissue that receive low and high
percentages (V5%-V100%) of the prescribed dose were asso-
ciated with the risk of subcutaneous fibrosis, and the
volume receiving 50%, 80%, and 100% (V50%-V100%) of the
prescribed dose was associated with fair/poor cosmesis
scores. These results generally demonstrate a higher inci-
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Fig. 2. Dose volume histogram of partial breast irradiation using two coplanar and two non-coplanar photon beams. Lumpec-
tomy cavity (purple), planning target volume (red), ipsilateral breast (yellow), contralateral breast (cyan), ipsilateral lung
(blue), contralateral lung (green), and heart (orange) are depicted.
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Values are presented as number (%). PTV, planning target volume.
Table 2. Technical feasibility of radiation treatment planning using three-dimensional conformal radiotherapy
PTV Ipsilateral Contralateral Ipsilateral Contralateral Heart Thyroid Overallcoverage breast breast lung lung
No variation 26 (61.9) 36 (85.7) 33 (78.6) 37 (88.1) 40 (95.2) 41 (97.6) 41 (97.6) 18 (42.9)
Minor variation 16 (38.1) 2 (4.8) 5 (11.9) 3 (7.1) 0 0 0 14 (33.3)
Major variation 0 4 (9.5) 4 (9.5) 2 (4.8) 2 (4.8) 1 (2.4) 1 (2.4) 10 (23.8)
Table 3. Pretreatment factors impacting technical feasibility using three-dimensional conformal radiotherapy
p-value
Univariate analysisa) Multivariate analysisb)
Tumor location (lower) 0.203 -
Tumor location (inner) 0.341 -
Tumor side (left) 0.600 -
Ipsilateral breast volume (> 900 mL) 0.476 -
PTV (> 130 mL) 0.020 -
PTV/IB (> 0.16) 0.014 0.015 (OR, 7.0; 95% CI, 1.4-33.7)
Values are presented as number (%). PTV, planning target volume; PTV/IB, planning target volume to ipsilateral breast vol-
ume ratio; OR, odds ratio; CI, confidence interval. a)Fisher’s exact test was used due to small sample size (less than five cases
in any cell), b)Logistic regression test was performed.
PTV, planning target volume; IB, ipsilateral breast volume; PTV/IB, planning target volume to ipsilateral breast volume ratio.
Table 4. Dosimetric features in cases with major variations of treatment planning using three-dimensional conformal
radiotherapy
Case no. PTV IB PTV/IB Side Location Location Major(mL) (mL) (inner) variation
2 120.82 818.22 0.147 Left Lower No Contralateral breast
9 141.47 1,446.69 0.097 Left Upper No Thyroid
13 148.16 763.54 0.194 Left Upper No Ipsilateral breast,
contralateral breast
18 155.32 864.37 0.179 Right Upper No Ipsilateral breast
23 63.59 337.58 0.188 Right Upper No Contralateral breast
27 134.42 807.71 0.166 Right Lower No Ipsilateral lung,
contralateral lung, heart
28 175.94 764.87 0.23 Left Lower Yes Ipsilateral breast
31 88.28 528.81 0.166 Left Upper Yes Ipsilateral breast,
ipsilateral lung
36 74.08 487.98 0.151 Left Upper No Contralateral lung
42 167.72 1,031.22 0.162 Left Upper No Contralateral breast
dence of late normal tissue toxicity compared with those 
reported in the RTOG trials with 3-DCRT APBI [9,10]. In
order to substantially reduce the risk of adverse normal 
tissue effects, the authors suggested the use of more restric-
tive dose-volume constraints than those currently defined by
the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B39/RTOG 0419 trial. However, the authors noted
a potential limitation of the retrospective analysis in that a
baseline postsurgical evaluation was not performed, thus
making it difficult to assess the true adverse effects of radia-
tion-induced normal tissue toxicity; therefore, additional
results are needed before these suggestions can be accepted.
In our study, the ipsilateral breast dose limitations of V50%
< 50% were not acceptable in four cases (9.5%), while, there
was no violation of the ipsilateral breast dose limitation in
the RTOG 0319 study [9]. As a possible explanation for the
discordance between the two studies, we can consider the
differences in breast size. In a recent phase I/II study of APBI
with 3-DCRT in Western countries [19], the median ipsilat-
eral breast volume, 1,698 mL (range, 647 to 3,627 mL), was
2-fold larger than that in our study, 784 mL (range, 337 to
1,446 mL). The median V50% of the ipsilateral breast was
41.9% in our study (data was not shown), and this parameter
was larger than that reported in Western countries (37.9%).
In a Korean study of dosimetric comparison of PBI with four
different techniques, mean V50% in 3-DCRT was 57.6%, and
this parameter is similar to our data [20], meaning that
relatively larger portions of the normal breast tissue might
be exposed to low-dose irradiation (V50%) in Korean women
with small breasts. In addition, four cases (9.5%) showed
major variations in contralateral breast dose limitations. In
these cases, only one had an ipsilateral breast dose violation.
There was a limitation in the gantry angle of the linear
accelerator with regard to fitting the ipsilateral breast dose
limitation, and this could cause partial contralateral breast
irradiation in small breasts. Comparatively large normal
breast tissue could be exposed to low-dose irradiation by use
of PBI with 3-DCRT while relatively homogeneous doses
could be delivered to the target volume. Therefore, the
ipsilateral breast dose limitation in the RTOG 0319 study
might not be applicable to Korean women with small-
volumed breasts.
Conclusion
Although we could not draw the same conclusion regard-
ing technical feasibility as in the RTOG 0319 study, we can
conclude that the PTV/IB ratio affects the technical feasibility
of 3-DCRT planning for PBI and it can be performed in Ko-
rean breast cancer patients with PTV/IB  0.16, even those
with small breasts. In addition, further study is needed in
order to determine feasible dose limitations, particularly
breast limitation, when PBI with external-beam irradiation
is administered to small-breasted patients.
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